Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Eli Lilly & Co., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The current ratio for the period examined demonstrates considerable fluctuation. Initially, the ratio exhibited a generally positive trend, followed by a significant decline, and then a period of instability before a recent increase. This analysis details these observed patterns.

Initial Period (2005-2007)
From 2005 to 2007, the current ratio increased from 1.89 to 2.33. This indicates a strengthening of the company’s ability to cover its short-term liabilities with its short-term assets during this period. The increase suggests improved liquidity and a reduced risk of short-term solvency issues.
Significant Decline (2008)
A substantial decrease in the current ratio was observed in 2008, falling to 0.95. This represents a significant weakening in the company’s short-term liquidity position. The decline suggests a potential difficulty in meeting short-term obligations without relying on external financing or asset liquidation.
Recovery and Fluctuations (2009-2016)
The ratio partially recovered in 2009 to 1.90, but then experienced ongoing fluctuations. It ranged between 1.32 and 2.09 over the years 2011 through 2016. This period suggests an inconsistent approach to managing short-term assets and liabilities, or external factors impacting both components. The ratio generally remained above 1.0, indicating the company generally maintained sufficient current assets to cover current liabilities, but with varying degrees of comfort.
Recent Trends (2017-2025)
From 2017 to 2019, the current ratio decreased from 1.32 to 1.16. A slight recovery occurred in 2020 (1.40), followed by a decline to 1.05 in 2021. The ratio then decreased further to 0.94 in 2022, before increasing to 1.15 in 2023 and 1.58 in 2025. This recent increase suggests an improvement in short-term liquidity, potentially due to increased current assets or decreased current liabilities. The volatility observed in this period warrants further investigation to understand the underlying drivers.

Overall, the current ratio has demonstrated a lack of consistent stability over the examined period. While the recent trend indicates improvement, the historical fluctuations suggest potential vulnerabilities in short-term financial management. Continued monitoring of this ratio is recommended to assess the company’s ongoing liquidity position.


Comparison to Competitors

Eli Lilly & Co., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Eli Lilly & Co., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)